Alemtuzumab: profile and news

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006
This Phase 3 study evaluated the use of Campath(R) (alemtuzumab for injection) as a first-line therapy for patients with B- cell chronic lymphocytic leukemia. ... - MSN Money

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006
This Phase 3 study evaluated the use of Campath® (alemtuzumab for injection) as a first-line therapy for patients with B-cell chronic lymphocytic leukemia. ... - WebWire (press release),

Other information

Indication
For treatment of B-cell chronic lymphocytic leukemia

Pharmacology
Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.

Mechanism Of Action
Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.

Drug Category
Antineoplastic Agents

Brand Names/Synonyms
Campath; Campath (ILEX Pharmaceuticals LP)

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Humanized anti-CD52 antibody

Chemical Formula
C6468H10066N1732O2005S40 >1CE1:L CAMPATH-1H:Light Chain 1 >1CE1:H CAMPATH-1H:Heavy Chain 2 >1CE1:L CAMPATH-1H:Light Chain 2

Half Life
~288 hrs

Drug Type
Approved Drug

# Accession No
BIOD00109

CAS Registry Number
Not Available